Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Werewolf Therapeutics (HOWL) Non-Current Debt (2023 - 2025)

Werewolf Therapeutics (HOWL) has disclosed Non-Current Debt for 3 consecutive years, with $21.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Debt fell 15.46% to $21.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $21.7 million, a 15.46% decrease, with the full-year FY2024 number at $26.1 million, down 20.09% from a year prior.
  • Non-Current Debt was $21.7 million for Q3 2025 at Werewolf Therapeutics, down from $24.7 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $39.1 million in Q2 2023 to a low of $21.7 million in Q3 2025.
  • A 3-year average of $29.6 million and a median of $26.6 million in 2025 define the central range for Non-Current Debt.
  • Peak YoY movement for Non-Current Debt: plummeted 35.71% in 2024, then fell 1.82% in 2025.
  • Werewolf Therapeutics' Non-Current Debt stood at $32.7 million in 2023, then fell by 20.09% to $26.1 million in 2024, then fell by 17.01% to $21.7 million in 2025.
  • Per Business Quant, the three most recent readings for HOWL's Non-Current Debt are $21.7 million (Q3 2025), $24.7 million (Q2 2025), and $26.6 million (Q1 2025).